This study is testing an experimental drug called PCS6422 alongside a common chemotherapy drug, capecitabine, for people with advanced or metastatic breast cancer. Researchers want to see if PCS6422, when combined with capecitabine, can make your immune system more active against cancer. This trial is for adults aged 18 and older who have breast cancer that cannot be removed by surgery, including triple-negative breast cancer (TNBC) and HER2-negative breast cancer. You might be eligible if you can't use certain other treatments. The main goals are to see how many people respond to the treatment (Objective Response Rate) and to track any side effects. The study aims to enroll 90 participants, but its current status is unclear.

Study design

This is a Phase 2, open-label (meaning you and your doctors will know which treatment you are receiving), randomized study comparing PCS6422 plus capecitabine to capecitabine alone. It involves multiple centers and plans to enroll 90 participants.

What's involved

Not specified in the trial record.

Compensation

Not stated in the trial record.

Follow-up

The study will evaluate how many patients respond to treatment for up to 24 weeks after the end of treatment. Adverse events (side effects) will be monitored during treatment, for an average of 8 months.

AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.